drugset / Trial / NCT06438757

Trial of JYB1904 in Patients With Allergic Asthma

NCT06438757

Phase 2 Completed 69 enrolled Jemincare
RandomizedParallel-groupOpen-labelTreatment

Summary

This phase IIa trial is meant to evaluate the pharmacokinetics, pharmacodynamics and safety of JYB1904 in patients with allergic asthma.

Timeline

Start
2024-06-19
Primary completion
2025-11-20
Completion
2025-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject OZUREPRUBART Monoclonal antibody
Comparator Omalizumab Monoclonal antibody

Indications